Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
Zacks Investment Research | Apr 28, 2019 09:41PM ET
Fluidigm Corporation (NASDAQ:FLDM) is scheduled to release first-quarter 2019 results on May 2, before the opening bell.
In the last reported quarter, the company delivered a positive earnings surprise of 70%. Further, it has an average four-quarter positive surprise of 28.56%.
Let’s take a look at how things are shaping up prior to this announcement.
Which Way are Q1 Estimates Treading?
For the first quarter, the Zacks Consensus Estimate for revenues is pegged at $28.9 million, indicating a rise of 14.4% from the year-ago quarter. The consensus estimate for the bottom line is pegged at a loss of 10 cents per share, suggesting an improvement from the year-ago quarter’s loss of 16 cents per share.
Factors to Influence Q1
The company anticipates witnessing growth in mass cytometry consumables and service revenues in the to-be-reported quarter, backed by increase in utilization of its installed base consumables pull-through. In fact, the company expects growth in consumables pull-through for mass cytometry in 2019, with the projection ranging between $73,000 and $78,000.
Further, the company experienced robust sales growth for both Helios and Hyperion Imaging Systems in the first quarter that will contribute to anticipated growth in mass cytometry consumables and service revenues.
Additionally, the trend displayed by multisystem placements is likely to continue, due to immunology related research in pharma and biotech.
Fluidigm Corporation Price and EPS Surprise
the complete list of today’s Zacks #1 Rank stocks here .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.